Latham & Watkins Advises Atea Pharmaceuticals in its Initial Public Offering

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, has announced the pricing of its initial public offering of 12,500,000 shares of its common stock at a price to the public of US$24.00 per share. All of the shares of common stock are being offered by Atea. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Atea, were expected to be US$300 million, excluding any exercise of the underwriters’ option to purchase additional shares. Atea’s common stock trades on the Nasdaq Global Select Market under the ticker symbol “AVIR”. 

Latham & Watkins LLP represented Atea Pharmaceuticals in the transaction with a capital markets deal team led by partners Peter Handrinos and  Wesley Holmes, with associates Jennifer Yoon, Adam Johnson, N. Danny Shulman and Martha Anderson. Advice was also provided on FDA regulatory matters by partner Ben Haas and counsel Betty Pang, with associate Chad Jennings; on technology transactions and licensing matters by partner Judith Hasko, with associate Peggy Ni; on benefits and compensation matters by partner Matthew Conway, with associate Kirk Porter; on tax matters by partner Jocelyn Noll, with associate Lauren Bewley; and on other corporate matters by partner Jenna Cooper, with associate Katherine Marren.